Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Nov 11, 2026 · Filed Nov 12, 2026
The CEO of Perspective Therapeutics paid $38K out of pocket for Perspective Therapeutics shares. 1 other person at Perspective Therapeutics bought some too, in the same month. It was the first purchase in 20 months.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$37,943
Shares × reported transaction price
$25K–$100K
+79.1%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
First purchase in 20 months
Confirmed open-market purchases by the same insider in the available history
No
Compared with 6 earlier confirmed purchases
2 distinct insiders in 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
This purchase equals about 1.6% of the CEO's reported total pay for fiscal 2025 ($2.4M)
Purchase value ÷ the CEO's total from the Summary Compensation Table, as tagged in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-04-16. The proxy names Johan (Thijs) Spoor as CEO for that year. A size comparison, not a judgement
2 days after results of Nov 9, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $0.8252 on Nov 11, 2026, within 5% of its 52-week low, after a 70% drop over the previous 30 trading days
52-week range $0.7864 (Nov 10, 2026) to $5.65 (Feb 19, 2026), 1% of the way up, from 250 adjusted closes. 30 trading days earlier: $2.75 on Sep 30, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
The first open-market purchase by any CATX insider since Mar 2025
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
Insider buying
Traded Nov 12 · filed 1 day later
Perspective Therapeutics's Chief Medical Officer paid $30K out of pocket for Perspective Therapeutics shares. 1 other person at Perspective Therapeutics bought some too, in the same month. Shares held went up 24% with this purchase.
Insider buying
First insider buy since Mar 2025Traded Nov 11 · filed 2 days later
Perspective Therapeutics's Chief Medical Officer paid $5K out of pocket for Perspective Therapeutics shares. 1 other person at Perspective Therapeutics bought some too, in the same month. It was the first purchase in over a year.
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
Johan M. Spoor, Chief Executive Officer's past purchases, 90 days after disclosure: 3 buys, median −28.1 pts vs S&P 500, beat it 1 of 3 times. Past results, not a forecast.
